Europe’s IMI adopts CDISC standards for research projects

By Gareth Macdonald

- Last updated on GMT

Europe’s IMI adopts CDISC standards for research projects
Europe’s Innovative Medicines Initiative (IMI) has adopted the Clinical Data Interchange Standards Consortium’s (CDISC) standards for all future projects in a move announced this week.

Under the new agreement with CDISC, the IMI – a €2bn (€2bn) EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA) organisation designed to promote safe drug development – will provide educational support and reference materials for the data standards to members.

The deal will also grant CDISC membership and access to the CDISC Members Only Area and portals to all academic institutions, small and medium-sized enterprises and other organisations receiving IMI funding.

Ann Martin, Principal Scientific Manager for Knowledge Management at IMI said: “To effectively manage information across a variety of projects requires a common format at the elemental level.

Our stakeholders felt strongly that it is good practice to adopt data standards. CDISC already provides such standards enjoying wide adoption in the pharmaceutical industry. The CDISC standards therefore could be considered as a default standard for research conducted through the IMI projects​.”

IMI member projects range from finding new biomarkers to educating researchers and using electronic health records for various research purposes.

CDISC’s standards – which are widelyused​ in the contract research sector - are consensus-based data formats that provide a common ‘language’ for data exchange during protocol design, data analysis and reporting.

CEO Rebecca Kush said: “CDISC is extremely pleased to formalise this relationship with IMI,” adding that “We have thoroughly enjoyed working with IMI to date, and we feel that this will be an invaluable mutually beneficial partnership that can generate standards-based innovations to streamline the development of new therapies and medical knowledge that will benefit patients worldwide​.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars